NCT04482959View on ClinicalTrials.gov

Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

December 30, 2021

Study Completion Date

February 1, 2022

Conditions
Myoma;Uterus
Interventions
DRUG

Carbetocin

(1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin

DRUG

Sodium chloride 0.9%

Physiological solution will be used as placebo

Trial Locations (1)

050

Faculty of Medicine, Al Mansurah

All Listed Sponsors
lead

Mansoura University Hospital

OTHER

NCT04482959 - Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy | Biotech Hunter | Biotech Hunter